ArticleCell biochemistry and biophysics2026
Juanbi Qianggu Formula Alleviates Rheumatoid Arthritis by Suppressing the TNF-α/NF-κB Signaling Pathway.
Article in Cell biochemistry and biophysics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Juanbi Qianggu Formula (JBQGF) is a traditional Chinese medicine prescription with demonstrated clinical efficacy in rheumatoid arthritis (RA), yet its pharmacological mechanisms remain unclear. This study investigated whether JBQGF attenuates RA-associated inflammation by inhibiting the TNF-α/NF-κB signaling pathway. In a collagen-induced arthritis (CIA) mouse model, JBQGF significantly ameliorated joint swelling, bone erosion, and systemic inflammation, with efficacy comparable to methotrexate, and reduced serum and synovial TNF-α levels. In LPS-stimulated RAW 264.7 macrophages, JBQGF-containing serum suppressed NF-κB p65 nuclear translocation and downregulated TNF-α, iNOS, and COX-2 expression. Transcriptomic profiling of synovial tissue, coupled with functional rescue assays, revealed that JBQGF directly suppresses TNFAIP2 expression via the primary NF-κB axis rather than secondary TNF-α depletion, thereby disrupting an NF-κB/TNFAIP2/ROS inflammatory cascade. These findings indicate that JBQGF targets the TNF-α/NF-κB pathway at multiple nodes to restore cellular inflammatory and redox balance, providing a mechanistic basis for its therapeutic effects in RA.
Indexed as
Identifiers
42789014What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.